HNGE

Hinge Health, Inc.

Fundamental data last updated:October 24, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Healthcare Information Services

Exchange

NYSE

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Hinge Health, Inc. develops health care software for joint and muscle health. The company designs its platform to address a musculoskeletal care, acute injury, chronic pain, and post-surgical rehabilitation. It also provides various administrative and operations support services. The company was founded in 2012 and is headquartered in San Francisco, California.

 


Analyze HNGE on TradingView

VALUATION

P/E

-7.03

Market Cap ($M USD)

$4.25B

Forward P/E

11.54

PEG

0.07

PRICE TO SALES

6.58

PRICE TO BOOK

13.87

EV / EBITDA

-7.77

5-Year Average P/E

Free Cash Flow Yield

4.85%

DCF Value

$-166.03

Graham Number

N/A

Price to FCF

20.62

EV to FCF

19.75

Earnings Yield

-14.22%

FCF Yield

4.85%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$7.82

Next Year EPS Growth Estimate

$4.76

Next Year Revenue Growth Estimate

$1.57B

Return on Equity (ROE)

-167.01%

FREE CASH FLOW

Operating Margin

-81.60%

Debt-to-Equity

0.02

Piotroski F-Score

4

Altman Z-Score

2.82

Return on Invested Capital (ROIC)

-167.82%

Current Ratio

1.22

Quick Ratio

1.19

Net Debt to EBITDA

0.35

Interest Coverage

0.00

Gross Profit margin

80.96%

FCF PER SHARE

$2.62

REVENUE PER SHARE

$8.22

Analyze HNGE on TradingView

Gainseekers Quantitative Analysis

Summary

HNGE’s valuation is a perplexing mix of potential and peril. Despite a Forward P/E of 11.77 suggesting future profitability, the current Price/Earnings ratio of -8.63 and a DCF Value deeply negative at -155.52 indicate severe mispricing concerns. The Altman Z-score of 3.06 suggests financial stability, yet the Earnings Yield of -11.59% warns of ongoing losses. The market seems to have priced in a turnaround, but the gap between current pricing and intrinsic value raises red flags about execution risks. Investors must weigh these contradictions carefully.

AI Exposure / Tech Reliance

Operating within the Medical - Healthcare Information Services industry, Hinge Health is strategically positioned to leverage AI and tech advancements. As healthcare increasingly integrates digital solutions, the company's tech-driven approach could enhance patient outcomes and operational efficiency. This alignment with modern tech trends may offer resilience against industry disruptions.

The Bull Case

For the GARP investor, Hinge Health presents an intriguing opportunity. The Forward PEG ratio of 0.07 signals potential undervaluation relative to growth, while a robust Gross Profit Margin of 80.80% highlights pricing power. Despite a negative ROIC, the FCF Yield of 4.67% suggests some capital efficiency. These metrics, coupled with a Piotroski F-Score of 4, hint at underlying strengths that could drive future profitability.

The Bear Case

However, the bear case is hard to ignore. With a Price/Book ratio of 14.14 and Price/Sales of 6.83, the stock appears overvalued against its tangible assets and revenue. The negative EPS of -$6.49 and Operating Margin of -81.60% underscore severe profitability issues. Trading just 11% below its 52-week high, the stock seems technically overextended, raising concerns about its sustainability at these levels.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$65.82

Institutional Ownership %

1-Year Beta

1.65

Insider Buying % (6 Mo)

Distance to 52-Week High

13.16%

Distance to 52-Week Low

45.26%

EARNINGS SURPRISE %

15.38%

50-DAY SMA

$45.86

200-DAY SMA

$47.36

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.